Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
460 Efficacy of adding anti-PD1 immunotherapy to dabrafenib + trametinib (DT) at progression in BRAFv600e mutated anaplastic thyroid carcinoma (BRAFm-ATC)
Compose a Response to This Article
Other responses
No responses have been published for this article.